

## PEOPLE

British Biotech (Oxford, UK) has announced the resignation of **Giles Campion** as director of research and development and chief medical officer at the end of September 2001. No replacement has been named, and R&D functions will report directly to CEO Elliot Goldstein.

Psychiatric Genomics (Gaithersburg, MD) has announced the appointment of **Richard E. Chipkin** as CEO. Dr. Chipkin joins the company from Schering-Plough, where he served most recently in the global business development group.

**Alfred J. Fernandez** has been appointed executive vice president and chief financial officer at Genta (Berkeley Heights, NJ). As CFO, he replaces **Gerald Schimmoeller**, who is leaving the company for personal reasons. Mr. Fernandez was most recently senior vice president and CFO of MetroCom, a telecommunications company.



**Barbara K. Finck** has joined Eos Biotechnology (S. San Francisco, CA) as vice president, clinical development. Dr. Finck was most recently medical director at Immunex, where she was responsible for clinical development of its rheumatoid arthritis drug Enbrel.

**Claes Glassell** has been appointed president and chief operating officer of Cambrex (E. Rutherford, NJ). Mr. Glassell was also elected to the company's board. He joined Cambrex in 1994 as president of the pharmaceuticals group and was most recently executive vice president and COO.

Targacept (Winston-Salem, NC), a spinoff of R.J. Reynolds Tobacco, has named **Tamar Howson** and **Mark Skaletsky** to its board of directors. Ms. Howson is a special limited partner in Care Capital, a venture capital firm, and previously served as the senior vice president and director, worldwide business development for SmithKline Beecham. She also managed S.R. One, SKB's \$100 million venture fund. Mr. Skaletsky is chairman and CEO of Althexis, former chairman of the board of directors of the Biotechnology Industry Organization, and former president of the Massachusetts Biotechnology Council.

Exelixis (S. San Francisco, CA) has named **Jeffrey R. Latts** chief medical officer and senior vice president, responsible for clinical development. Dr. Latts joins the company from Berlex Laboratories, where he

served as vice president of clinical R&D and chief medical officer.

Drug delivery company Spherics (Warwick, RI), has announced the appointment of **David J. Livingston** as president and CEO. Dr. Livingston was most recently executive director of Rhode Island's Slater Center for Biomedical Technology, and was previously president and CEO of Praelux Inc. **Ben Bronstein**, a venture partner at Zero Stage Capital, who served as interim president and CEO of Spherics, is remaining as a director.

Palatin Technologies (Princeton, NJ) has appointed **Perry B. Molinoff** to the position of executive vice president of research and development. Dr. Molinoff was most recently vice president of the division for neuroscience and genitourinary drug discovery for the Bristol-Myers Squibb Pharmaceutical Research Institute.

Antex Biologics (Gaithersburg, MD) has named **Jeffrey V. Pirone** executive vice president and CFO. He joins Antex from Orbital Sciences, where he served in the same capacity.

**Li-Hsien "Lily" Rin-Laures** has joined Hyseq (Sunnyvale, CA) as senior vice president and general counsel. Dr. Rin-Laures was most recently a partner at the law firm Marshall, Gerstein and Borun, where she served as outside patent counsel to Hyseq for the past two and a half years.

**Stephen R. Seiler** has been named CEO and a member of the board of directors of Hybridon (Cambridge, MA). Previously, Mr. Seiler served as executive vice president, planning investment and development at Elan Corporation.

Myriad Genetics (Salt Lake City, UT) has named **Edward A. Swabb** senior vice president and head of development of its Myriad Pharmaceuticals subsidiary. Dr. Swabb was previously executive director of clinical research at Pharmacia.

**Jeff R. Swarz** has joined Life Science Group (Greenwich, CT), a financial services company, as a managing director. Dr. Swarz spent 15 years as a senior biotechnology analyst at Goldman Sachs and Credit Suisse First Boston, and for the past two years he has been involved in private equity and investment banking.

Geron (Menlo Park, CA) has announced the appointment of **Patrick J. Zenner** to its board of directors. Mr. Zenner recently retired as president and CEO of Hoffman-La Roche.